July 11, 2024 Atomic Spectroscopy Clinical Research/Diagn. Lab Top-10 Life Science Tools

Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology

myeloMATCH Precision Medicine Clinical Trial Leverages Next-Day Genomic Testing to Quickly Match Patients with Appropriate Trials Across North America WALTHAM, Mass.–(BUSINESS WIRE)– To help accelerate research into new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is partnering with the National... Read more

June 19, 2024 Clinical Research/Diagn. Environ, Ag./Food & Bev Lab Top-10 PAI Top-10 PR/Corporate

Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics

Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics WASHINGTON, June 19, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher” or the “Company”), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr.... Read more

June 3, 2024 Atomic Spectroscopy Clinical Research/Diagn. Lab Top-10 Mass Spectrometry

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research The Thermo Scientific™ Stellar™ mass spectrometer combines speed and sensitivity to advance precision medicine ANAHEIM, Calif.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Stellar™ mass spectrometer (MS), a new solution that combines fast... Read more

May 2, 2024 Clinical Research/Diagn. Lab Top-10

Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech

ELITech is a differentiated, fast growing and profitable provider of systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITech offers the proprietary, fully automated sample-to-answer (S2A) systems InGenius® and BeGenius® for molecular testing in mid-sized hospitals Diversified ELITech MDx assay portfolio focused on esoteric infectious disease testing ELITech has its R&D,... Read more

April 26, 2024 Clinical Research/Diagn. Lab Top-10 Liq. Handling & Robotics

Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

New MBT Pathfinder® IVD robot for automated MALDI Biotyper® target preparation New LiquidArray® MTB-XDR panel for simultaneous detection of M. tuberculosis complex bacteria, and their resistances to five WHO-recommended second-line drugs against multidrug-resistant tuberculosis Pending ELITech acquisition has received all regulatory clearances; closing now expected in the second quarter of 2024 BARCELONA, Spain–(BUSINESS WIRE)– At... Read more

February 28, 2024 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup

ELITechGroup is a differentiated, fast growing and profitable systems and assay provider for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITechGroup offers the proprietary, fully automated sample-to-answer (S2A) molecular diagnostic (MDx) systems InGenius® and BeGenius® for mid-sized hospitals and esoteric testing Large and diversified ELITech MDx assay portfolio is focused on pathogens and viral... Read more

February 6, 2024 Clinical Research/Diagn. Lab Top-10 Microscopy

Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems

Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems Acquisition Complements Bruker’s Preclinical Imaging Portfolio with In-Vivo Optical Imaging TUCSON, Ariz.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced that it has acquired Spectral Instruments Imaging LLC, a leader in preclinical in-vivo optical imaging systems. This acquisition fills a gap in... Read more

February 5, 2024 Bio/Pharma/CRO Clinical Research/Diagn. Environ, Ag./Food & Bev Lab Top-10 M&A, Partnerships PAI Top-10 Product Launch

Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development

Danaher Launches Collaboration with Cincinnati Children’s Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expand genetic diversity of screening, accelerate therapy development,... Read more

December 29, 2023 Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships

Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform

The transformative point of care solution will complement Roche’s centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease areas LumiraDx’s technology integrates multiple Point of Care tests on a simple to use single instrument and brings more affordable and accessible testing to patients worldwide Under the terms of the agreement,... Read more

December 4, 2023 Clinical Research/Diagn. M&A, Partnerships

Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes

Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche’s in-house assets Lead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbidities Under the terms of... Read more